Showing results (641-650 of 977) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|February 17, 2026
Phase II trial of anlotinib-chemotherapy combination in pretreated HER2-negative metastatic breast cancer: therapeutic efficacy and proteomic biomarker profilingTing Xu, Quan Gu, Shiyi Li, et al.
NPJ Breast Cancer|February 3, 2026
Impact of estrogen receptor expression levels on chemo-responsiveness and prognosis of breast cancer patients treated with neoadjuvant chemotherapyKyungah Bai, Hyun-Jung Sung, Yul Ri Chung, et al.
NPJ Breast Cancer|January 23, 2026
Spatial gene expression analysis reveals drivers of extremely early lymph node metastasis in breast cancerSatoi Nagasawa, Keiko Kajiya, Erina Ishikawa, et al.
NPJ Breast Cancer|January 24, 2026
CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapyXueting Qin, Yixin Chang, Yuanyuan Qiu, et al.
NPJ Breast Cancer|January 29, 2026
The association between local therapies and survival among patients with metastatic inflammatory breast cancerTanun Jitwatcharakomol, Yevgeniya Gokun, Steve A Walston, et al.
NPJ Breast Cancer|January 21, 2026
CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancerWei Shi, Yi Luo, Yizhuo Wang, et al.
NPJ Breast Cancer|March 2, 2023
TGFβ-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progressionShayin V Gibson, Elena Tomas Bort, Lucía Rodríguez-Fernández, et al.
NPJ Breast Cancer|March 6, 2023
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual diseaseShane R Stecklein, Bruce F Kimler, Rachel Yoder, et al.
NPJ Breast Cancer|February 24, 2023
PROCURE European consensus on breast cancer multigene signatures in early breast cancer managementGiuseppe Curigliano, Fatima Cardoso, Michael Gnant, et al.
NPJ Breast Cancer|February 4, 2023
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trialMaria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, et al.
Pageof 98